TMEM86A

Across TCGA pan-cancer cohorts, TMEM86A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM86A data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TMEM86A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM86A expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where TMEM86A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.173	0.791	.038	6	view →
LSCC	OS	Median	III,IV	0.970	0.640	.033	4	view →
LUAD	DFS	Quartile	III,IV	0.462	0.891	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TMEM86A–PDAC (OS)

Open the PDAC breakdown →